Navigation Links
Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
Date:9/28/2011

GREENWOOD VILLAGE, Colo., Sept. 28, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has received notification of allowance of its two patent applications on Zertane™ combinations with erectile dysfunction (ED) drugs in Canada.  This allowance includes claims directed to the use of Zertane™ with a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors commonly used for the treatment of ED to address concurrent premature ejaculation (PE) and ED. The allowed claims also include composition of matter claims, such as claims directed to a pharmaceutical composition or a kit containing Zertane™ and a PDE5 inhibitor. Similar patent applications are being prosecuted worldwide.

It has been reported that ED and PE can co-exist in up to 30% of patients. There may be patients with ED who are effectively treated with phosphodiesterase type 5 inhibitors but who may have PE.  The patented combination of PE and ED drugs addresses this substantial group of patients.

"This first allowance of these two patents in Canada is an important milestone in Ampio's strategy to continue the development of its sexual dysfunction portfolio by first obtaining strong intellectual property protection," said Don Wingerter Ampio's CEO. "We are very excited by this development as we anticipate it will help increase our growing out-licensing activity for this product line," continued Don Wingerter.

About Zertane

The active ingredient in Zertane™ is a drug that was approved for marketing as a noncontrolled analgesic in 1995. In two Phase III clinical trials, Zertane™ has proven to be an effective oral medication to treat PE in men. Premature ejaculation
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
2. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
3. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
4. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
5. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
6. Ampio Pharmaceuticals Set to Join Russell 3000 Index
7. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
8. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
9. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
10. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
11. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 North American lighting leader ... 100 Award for the new OSRAM ITOS ® PHASER ... light module for microscopy, endoscopy and surgical head lamps that ... higher efficacy and lamp life. "We,re honored to ... the most innovative new technologies of the past year," said ...
(Date:8/27/2014)... 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... pharmaceutical development, clinical trial manufacturing, and advanced analytical and ... it will participate at the upcoming Rodman & Renshaw ... held in New York . The ... September 9, 2014 at the New York Palace Hotel. ...
(Date:8/27/2014)... 27, 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... following financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over ... loss for the quarter of $240,156 compared to net income ... For the nine months ended June 30, ...
Breaking Medicine Technology:OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
... 2011 Berg Biosystems, LLC (Berg) and GNS Healthcare, ... that they have entered into a joint venture named ... to accelerate advancements in critical biomedical research.  MAP will ... drug discovery platform, and GNS,s patented supercomputer-driven ...
... FRISCO, Texas, March 2, 2011 Assured Pharmacy (Pink Sheets: ... prescription medications to more than 3,000 sufferers of chronic pain ... the month of December 2010 were $1,514,984 which equates to ... percent when compared with total sales of $1,348,344 for December ...
Cached Medicine Technology:Berg Biosystems and GNS Healthcare Announce Joint Venture - MAP Biosystems 2Berg Biosystems and GNS Healthcare Announce Joint Venture - MAP Biosystems 3Assured Pharmacy Reports Same Store Sales for the Month of December 2010 2Assured Pharmacy Reports Same Store Sales for the Month of December 2010 3
(Date:8/27/2014)... The National League for Nursing is ... RN, FAAN, became the inaugural director of the ... the Science of Nursing Education , effective August 11. ... NLN Home for Transformative Excellence, established with the League’s ... , Under Dr. Dennis’s leadership, the NLN/Chamberlain Center ...
(Date:8/27/2014)... August 28, 2014 Delta, a reliable ... added several practical Cat D7R Dozers to its ... senior spokesman has announced that all these items are ... promotion is to expand Delta’s market share in the ... to launch the special offer; he has much confidence ...
(Date:8/27/2014)... Millennium Treatment Group is proud to ... Mental Health Counselors Association (FMHCA). The addiction treatment facility ... sure to provide. , FMHCA is an organization dedicated ... mental health counselors. The organization was founded in 1976 ... and since then, it has served the state’s mental ...
(Date:8/27/2014)... NY (PRWEB) August 27, 2014 The ... Team ) is holding free events about “ Sexuality ... speaker Liz Treston. These straightforward and entertaining discussions are ... at Bussani Mobility (501 Concord Avenue, Mamaroneck, NY) and ... Central Avenue, Bethpage, NY). , The New York ...
(Date:8/27/2014)... 27, 2014 The American ... for the management and treatment of pulmonary arterial ... Arterial Hypertension in Adults: CHEST Guideline, in the ... for clinicians, and provide the latest and most ... Pulmonary Hypertension Association (PHA) – the country’s ...
Breaking Medicine News(10 mins):Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 2Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 3Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 4Health News:Reliable Supplier Delta Adds New Items To Its Used Bulldozer Collection 2Health News:Millennium Treatment Group Sponsors Florida Mental Health Counselors Association 2Health News:Bussani Mobility Sponsors New York Mobility Club Meetings September 9 & October 7 for People with Disabilities, Sexuality & Intimacy Discussed by Advocate Liz Treston 2Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2
... C, s * po ... media attention has focused on the presence of trace levels of ... the U.S. Food and Drug Administration (FDA) have studied perchlorate extensively ... consumers, including sensitive sub-populations like infants. Trace levels of perchlorate ...
... Inc. (Nasdaq: DIET ), a leading provider ... announced that it received a notice from the NASDAQ Stock ... securities has fallen below $35 million, the minimum level required ... NASDAQ Marketplace Rule 4310(c)(3)(B). The Company will have until ...
... Inc. will host an upcoming Illinois Venture Capital Association ... The event will be held at the UBS Tower, ... Wednesday, April 22. Reginald McGaugh, Managing Director, will ... with executives from some of the most successful companies ...
... Office (GAO) today announced the appointment of Charles ... WellPoint, Inc. (NYSE: WLP ), to ... advisory body established by the American Recovery and ... helps meet legislators, needs for timely and reliable ...
... April 3 AstraZeneca (NYSE: AZN ) ... Drug Administration (FDA) posted to its web site -- ... 8, 2009 Psychopharmacologic Drugs Advisory Committee (PDAC) meeting. The ... efficacy data provided in supplemental new drug applications (sNDA) ...
... In its continued effort to help men and women from the United Kingdom ... leader in hair restoration, has opened its London center. , ... (PRWEB) April 3, 2009 ... Kingdom (UK) and Europe who are thinning and balding, Nu/Hart Hair Clinics ...
Cached Medicine News:Health News:International Formula Council (IFC) Reassures Parents about Perchlorate and the Safety of Infant Formula 2Health News:eDiets.com(R) Receives NASDAQ Notice Regarding Market Value of Listed Securities 2Health News:eDiets.com(R) Receives NASDAQ Notice Regarding Market Value of Listed Securities 3Health News:Houlihan Smith to Host Illinois Venture Capital Association Luncheon Seminar on Midwest Healthcare Investing 2Health News:Charles Kennedy, M.D., Vice President for Health Information Technology, WellPoint, Inc., Appointed to National Health I.T. Policy Committee 2Health News:Charles Kennedy, M.D., Vice President for Health Information Technology, WellPoint, Inc., Appointed to National Health I.T. Policy Committee 3Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 2Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 3Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 4Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 5Health News:Nu/Hart, World Leader in Hair Transplants, Opens London Centre 2Health News:Nu/Hart, World Leader in Hair Transplants, Opens London Centre 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: